



(51) International Patent Classification:

C07K 16/28 (2006.01) **C07K 14/725** (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:

PCT/US2018/035492

(22) International Filing Date:

31 May 2018 (31.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/514,634	02 June 2017 (02.06.2017)	US
62/514,574	02 June 2017 (02.06.2017)	US
62/660,908	20 April 2018 (20.04.2018)	US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **SASU, Barbra Johnson**; 2125 Bryant Street,
#316, San Francisco, California 94110 (US). **DETLING,**
Danielle Elizabeth; 309 Scott Street, #A, San Francisco,

California 94117 (US). **SOMMER, Cesar Adolfo**; 155
North El Camino Real, #31, San Mateo, California 94401
(US). **YEUNG, Yik Andy**; 288 Avalon Drive, South San
Francisco, California 94080 (US). **HAMZE, Moustafa**
Marc; 8 Avenue du Maréchal Franchet d'Esperey, F-94130
Nogent-sur-Marne (FR).

(74) Agent: **JOSHI, Trupti P.** et al.; Cooley LLP, 1299 Penn-
sylvania Avenue, NW, Suite 700, Washington, District of
Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: CHIMERIC ANTIGEN RECEPTORS TARGETING FLT3




FIG. 1

(57) Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*